Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189956
Status:
COMPLETED
Last Update Posted:
2019-01-10
First Post:
2005-09-11
Brief Title:
Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE MVA-BN Smallpox Vaccine
Sponsor:
Bavarian Nordic
Organization:
Bavarian Nordic
Study Overview
Official Title:
Phase II Double-blind Randomised Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the study is to find the optimal dose for the smallpox candidate vaccine IMVAMUNE MVA-BN For this purpose the study compares IMVAMUNE MVA-BN administered at three different dose levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None